Bahaa Aly v. Valeant Pharmaceuticals Inter

1 F.4th 168
Court of Appeals for the Third Circuit·Decided June 16, 2021·No. 19-3326·Published·Cited by 9 cases

Opinion

PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

No. 19-3326

BAHAA ALY; TINA DAVIS; PHILLIP GARLAND;

ERINCH OZADA,

Appellants,

v.

VALEANT PHARMACEUTICALS INTERNATIONAL INC,

n/k/a Bausch Health Companies Inc.;

J. MICHAEL PEARSON; ROBERT L. ROSIELLO;

DEBORAH JORN;

ARI S. KELLEN; TANYA CARRO; HOWARD B.

SCHILLER

On Appeal from the United States District Court for the District of New Jersey 3:18-cv-17393

District Judge: Hon. Michael A. Shipp

Argued October 20, 2020

Before: GREENAWAY, JR., COWEN, and FUENTES, Circuit Judges.

(Opinion Filed: June 16, 2021)

Hung G. Ta [ARGUED] JooYun Kim Hung G. Ta, Esq. PLLC 250 Park Avenue, 7th Floor New York, NY 10177

Peter Safirstein Elizabeth Metcalf Safirstein Metcalf LLP 14 Penn Plaza, 9th Floor New York, NY 10122

Counsel for Appellants

Paul C. Curnin Craig S. Waldman [ARGUED] Simpson Thacher & Bartlett LLP 425 Lexington Ave. New York, NY 10017-3954

Richard Hernandez McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, NJ 07102

Benjamin Sokoly Winston & Strawn LLP

200 Park Avenue New York, NY 10166-4193

Joseph L. Motto Winston & Strawn, LLP 35 W. Wacker Drive Chicago, IL 60601

Matthew Petrozziello Elliot Greenfield Debevoise & Plimpton LLP 919 Third Avenue New York, NY 10022

Barry A. Bohrer Schulte Roth & Zabel LLP 919 Third Avenue New York, NY 10022

Counsel for Appellees

Michael J. Hampson [ARGUED] Mark B. Kramer Lawrence M. Rolnick Shelia A. Sadighi Rolnick Kramer Sadighi 1251 Avenue of the Americas 18th Floor New York, NY 10020

Counsel of Amicus Appellant

OPINION

FUENTES, Circuit Judge.

This is an appeal from the District Court’s order dismissing the complaint filed by individual shareholders of Valeant Pharmaceuticals Inc. (“Valeant” or the “Company”) as untimely. A class action (the “Class Action”) was filed against Valeant on behalf of investors who purchased its stock between February 23 and October 20, 2015 (the “Relevant Period”).1 Appellants were putative members of that class, but by December 2018, the District Court had still not ruled on class certification. Rather than wait for a decision, Appellants filed the present “opt-out” complaint bringing the same claims in their individual capacities (the “Individual Complaint”). The District Court dismissed the Individual Complaint as untimely under the applicable two-year limitations period, concluding that the tolling doctrine established in American Pipe & Construction Company v. Utah did not apply.2 That doctrine is central to this appeal.

Putative class members may recover as part of the class

or seek individual recourse, but they generally cannot do both.3 Complications tend to arise, however, around the class- certification stage. Members may initially intend to proceed as part of a class, but certification may be denied months or years later for reasons outside their control.4 Alternatively, during the pendency of a class action, members may discover that their individual claims are more valuable than those of the class and decide to pursue them in an opt-out complaint even if certification is likely. In either case, members are generally allowed to initiate an individual action, but may run into limitations issues given the delay. This is where American Pipe comes in.

When a class complaint is filed, American Pipe tolls the limitations period governing the individual claims of putative members. In the absence of such a rule, members may feel compelled to file duplicative individual suits bringing the same claims to protect their rights in the event certification is later denied. Otherwise, members would risk allowing their individual limitations periods to expire, potentially leaving them with no recourse in the long run. The doctrine is therefore intended to protect the rights of putative members while simultaneously avoiding needless identical lawsuits.

On appeal, the parties dispute whether American Pipe

tolling applies to individual claims that are filed before a certification decision is made. Appellants argue that the limitations period is tolled regardless of the point at which individual claims are filed. Appellees respond, and the District Court agreed, that members who wish to benefit from American Pipe must wait to file individual claims until after the court rules on certification, which Appellants did not do. For the reasons that follow, we conclude that American Pipe tolled the limitations period for the claims raised in the Individual Complaint. We will vacate and remand for further proceedings.

I.5

A.

The issue before us relates solely to the timeliness of the Individual Complaint, but we will provide a brief recitation of the facts for context. Valeant develops and manufactures

generic pharmaceuticals. Appellants purchased stock in Valeant during the Relevant Period. Prior to their purchase, the Company changed its business model to focus more on acquiring new drugs from other companies rather than developing its own. This approach was intended to significantly cut research-and-development costs and allow Valeant to market its drugs “more efficiently.”6 In the years that followed, Valeant made promising representations about the Company’s financial performance based on its new business model and approach. For instance, investors were assured that Valeant’s superior marketing and leadership resulted in a sales volume that was “greater than price in terms of [Valeant’s] growth,” and that the Company was maintaining “extremely high ethical standard[s]” in the process.7

As a result of this and other factors, the price of Valeant stock skyrocketed nearly 350% by the end of the Relevant Period. Appellants argue that this value was artificially inflated, however, and did not accurately represent the Company’s financial health. Specifically, they argue that the new business model “relied on a secret, Valeant-controlled pharmacy network” and “deceptive practices that exposed the Company to enormous risks.”8 This network purportedly allowed Valeant to charge third-party purchasers and patients much higher prices for its drugs than they were worth. Following a government investigation and private litigation against Valeant, the Company began disclosing its allegedly

fraudulent practices in late 2015. A number of Valeant executives were fired, and the value of its stock plummeted almost 90% by August 2016. The Company’s shareholders claim to have suffered over $76 billion in market capitalization losses as a result, which prompted the filing of numerous class and individual complaints, including the ones relevant to this action.9 B.

The first complaint in the Class Action was filed in October 2015. Several other class complaints alleging the same or similar violations were also filed around this time. Those actions were consolidated, and the operative consolidated complaint was filed on June 24, 2016 (the “Class Complaint”). The Class Complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act10 and Rule 10b- 5.11 Those claims were governed by a two-year statute of limitations or a five-year repose period, whichever came first.12

Valeant moved to dismiss the Class Complaint for failure to state a claim, which the District Court denied.

Free access — add to your briefcase to read the full text and ask questions with AI

Bahaa Aly v. Valeant Pharmaceuticals Inter, 1 F.4th 168 (3d Cir. 2021).

1 F.4th 168 (Bahaa Aly v. Valeant Pharmaceuticals Inter) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related